Since the beginning of the history of HIV infection, liver disease has been one of the major causes of morbidity and mortality in people living with HIV (PLWH) [1]. Even though the emergence of the new direct antiviral agents against hepatitis C virus (HCV) has been of great impact [2], the burden of liver disease still remains a matter of concern among physicians who treat PLWH due to the great number of patients with established cirrhosis, the high prevalence of drug abuse between patients with HIV-infection and the potential liver toxicity of some of the first antiretrovirals (ARV) and other co-medications.
